Background: Candidemia is an important nosocomial blood stream infection in critically ill patients. Although several studies have addressed candidemia, very few have reviewed the impact of Candida glabrata candidemia in Intensive Care Unit (ICU) patients. Materials and Methods: The medical records of ICU patients between 2006 and 2010 were reviewed retrospectively. The epidemiology, clinical features and mortality related risk factors among our adult ICU patients were seen. Results: Among 144 episodes of candidemia, C. glabrata (n = 26; 18.05%) was the third most common species isolated. The incidence of C. glabrata candidemia was 0.21/1000 ICU admissions. The most common risk factors were prior exposure to broad spectrum antibiotics (100%), central venous catheter (100%), mechanical ventilation (76.9%), diabetes mellitus (50%), age >65 years (46.15%). Urine (23%) was the most common source of C. glabrata candidemia. Overall in hospital 30 days mortality rate due to C. glabrata fungemia was 53.8%. Patients who were treated with fluconazole showed better outcome than patients treated with amphotericin B. Renal failure requiring hemodialysis was the significantly associated with mortality in our study. Conclusion: Candida glabrata was the 3 rd most common Candida causing candidemia in our ICUs with a incidence of 0.21/1000 ICU admissions. The outcome of ICU acquired C. glabrata candidemia was poor with 30 days mortality rate of 53.8%. Renal failure requiring hemodialysis was the only risk factor associated with mortality. Further studies are required to identify the other risk factors associated with mortality in C. glabrata candidemia.
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17.
Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685-702.
Cheng YR, Lin LC, Young TG, Liu CE, Chen CH, Tsay RW. Risk factors for candidemia-related mortality at a medical center in central Taiwan. J Microbiol Immunol Infect 2006;39:155-61.
Chen TC, Chen YH, Tsai JJ, Peng CF, Lu PL, Chang K, et al. Epidemiologic analysis and antifungal susceptibility of Candida blood isolates in southern Taiwan. J Microbiol Immunol Infect 2005;38:200-10.
Hung CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc 1996;95:19-28.
Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-8.
Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006;6:21.
Pfaller MA, Diekema DJ, International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: Global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004;10 Suppl 1:11-23.
Xess I, Jain N, Hasan F, Mandal P, Banerjee U. Epidemiology of candidemia in a tertiary care centre of north India: 5-year study. Infection 2007;35:256-9.
Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: Pathogenicity and antifungal resistance. J Hosp Infect 2002;50:243-60.
Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010;48:1366-77.
Safdar A, Bannister TW, Safdar Z. The predictors of outcome in immunocompetent patients with hematogenous candidiasis. Int J Infect Dis 2004;8:180-6.
Ruan SY, Lee LN, Jerng JS, Yu CJ, Hsueh PR. Candida glabrata fungaemia in intensive care units. Clin Microbiol Infect 2008;14:136-40.
Choi HK, Jeong SJ, Lee HS, Chin BS, Choi SH, Han SH, et al. Blood stream infections by Candida glabrata and Candida krusei: A single-center experience. Korean J Intern Med 2009;24:263-9.
Ruan SY, Huang YT, Chu CC, Yu CJ, Hsueh PR. Candida glabrata fungaemia in a tertiary centre in Taiwan: Antifungal susceptibility and outcomes. Int J Antimicrob Agents 2009;34:236-9.
Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:1298-302.
Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46:1723-7.
Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: Trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002;40:3551-7.
Kauffman CA. Fungal infections in older adults. Clin Infect Dis 2001;33:550-5.
Lockhart SR, Joly S, Vargas K, Swails-Wenger J, Enger L, Soll DR. Natural defenses against Candida colonization breakdown in the oral cavities of the elderly. J Dent Res 1999;78:857-68.
Akbar DH, Tahawi AT. Candidemia at a University Hospital: Epidemiology, risk factors and predictors of mortality. Ann Saudi Med 2001;21:178-82.
Ang BS, Telenti A, King B, Steckelberg JM, Wilson WR. Candidemia from a urinary tract source: Microbiological aspects and clinical significance. Clin Infect Dis 1993;17:662-6.
Marriott DJ, Playford EG, Chen S, Slavin M, Nguyen Q, Ellis D, et al. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care 2009;13:R115.
Bedini A, Venturelli C, Mussini C, Guaraldi G, Codeluppi M, Borghi V, et al. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect 2006;12:75-80.
Aquino VR, Lunardi LW, Goldani LZ, Barth AL. Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil. Braz J Infect Dis 2005;9:411-8.
Author information Girão E1, Levin AS, Basso M, Gobara S, Gomes LB, Medeiros EA, Costa SF. Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital. Med Mycol 2008;46:581-8.
Klevay MJ, Horn DL, Neofytos D, Pfaller MA, Diekema DJ, PATH Alliance. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2009;64:152-7.
Blot S, Vandewoude K, Hoste E, Poelaert J, Colardyn F. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata. J Hosp Infect 2001;47:308-13.